Cepheid Xpert HCV gets FDA authorization, waiver
July 2, 2024—Cepheid has received FDA de novo marketing authorization and CLIA waiver approval for its Xpert HCV, the first point-of-care hepatitis C RNA test.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
TechLab C. diff test receives European IVDR certification
July 1, 2024—TechLab, a part of SSI Diagnostica Group, announced that its C. Diff Quik Chek Complete test has received certification under European in vitro diagnostic medical device regulation.
Siemens offers NT‑proBNPII assay on Atellica Solution
June 28, 2024—Siemens Healthineers has added the NT‑proBNPII assay to its cardiac test menu on the Atellica Solution to help diagnose heart failure.
Spotfire R/ST Panel Mini gets special 510(k) clearance
June 27, 2024—BioMérieux announced that its Biofire Spotfire Respiratory/Sore Throat (R/ST) Panel Mini has received FDA special 510(k) clearance and CLIA waiver.
Proscia, Nucleai to broaden access to AI predictive biomarkers
June 26, 2024—Proscia has partnered with Nucleai, a spatial artificial intelligence biomarker company that maps protein expression and cellular interactions within tissue samples to predict therapeutic outcomes.
Horiba launches Yumizen H550 range with ESR and CBC/diff
June 25, 2024—Horiba announced that it has expanded its compact hematology instrument range with the launch of three models now with erythrocyte sedimentation rate onboard.
Risant acquires Cone Health
June 24, 2024—Cone Health and Risant Health have signed a definitive agreement under which Cone Health will become part of Risant Health, pending regulatory approvals.
FDA clears BioMérieux Vitek Reveal AST system
June 21, 2024—BioMérieux announced that its Vitek Reveal AST system has received FDA 510(k) clearance.
FDA clears Roche digital pathology solution for diagnostic use
June 18, 2024—Roche announced that its whole slide imaging system, the Roche Digital Pathology Dx, has received FDA 510(k) clearance.
Qiagen launches digital PCR assays for microbial applications
June 13, 2024—Qiagen has launched 35 wet-lab tested digital PCR microbial DNA detection assays for its digital PCR platform QIAcuity.